Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q3 2025
Net profit, assets, equity and cash flow for Q3 2025, against the same period a year earlier, from the published financial statements.
Net profit34.98 millionEGP · +54.2% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q3 2025 was about 34.98 million EGP, up +54.2% from 22.68 million EGP in Q3 2024.
Key lines against the same period a year earlier
This periodQ3 2024Change
Net profit34.98 million22.68 million+54.2%
Gross profit188 million101 million+85.2%
Total assets—575 million—
Total liabilities—525 million—
Shareholders' equity—50.05 million—
Total liabilities and equity—575 million—
Operating cash flow—22.04 million—
Investing cash flow-2.02 million28.04 million−107.2%
Financing cash flow-18.42 million17.04 million−208.1%
Net change in cash—67.12 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy